60 Degrees Pharmaceuticals (NASDAQ:SXTP) Earns Neutral Rating from HC Wainwright

60 Degrees Pharmaceuticals (NASDAQ:SXTP)‘s stock had its “neutral” rating restated by analysts at HC Wainwright in a research report issued on Monday,Benzinga reports.

60 Degrees Pharmaceuticals Trading Up 13.8 %

SXTP opened at $1.32 on Monday. The stock has a fifty day moving average price of $1.09 and a 200 day moving average price of $0.90. 60 Degrees Pharmaceuticals has a 1 year low of $0.70 and a 1 year high of $18.36. The stock has a market cap of $3.03 million, a price-to-earnings ratio of -0.13 and a beta of 5.36.

Insider Activity at 60 Degrees Pharmaceuticals

In other 60 Degrees Pharmaceuticals news, CEO Geoffrey S. Dow purchased 35,823 shares of the business’s stock in a transaction dated Monday, December 9th. The shares were acquired at an average price of $1.27 per share, for a total transaction of $45,495.21. Following the acquisition, the chief executive officer now owns 94,580 shares of the company’s stock, valued at $120,116.60. This trade represents a 60.97 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In the last quarter, insiders bought 66,372 shares of company stock valued at $82,410. 10.27% of the stock is owned by corporate insiders.

60 Degrees Pharmaceuticals Company Profile

60 Degrees Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development and commercialization of therapies for the prevention and treatment of infectious diseases in the United States. The company offers Arakoda for malaria preventative treatment. It also engages in the development of Tafenoquine (Arakoda regimen) that is in Phase IIb clinical trial for COVID-19 indications; Tafenoquine, which is in phase IIA clinical trials for babesiosis, fungal pneumonias, and candidiasis disease; and Celgosivir for respiratory viruses and dengue.